Agenus Inc AGEN:NASDAQ

Last Price$2.59Cboe Real-Time Last Sale as of 11:57AM ET 1/31/23
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.04(1.57%)
Bid (Size)$2.59 (1,600)
Ask (Size)$2.60 (1,900)
Day Low / High$2.57 - 2.65
Volume715.4 K

Agenus Microsatellite Stable Colorectal Cancer Trial Shows Efficacy -- Stock Gains Wednesday

1:41PM ET 6/29/2022 MT Newswires
Agenus (AGEN) said Wednesday that data from the phase 1b study of botensilimab and balstilimab showed strong efficacy in patients with microsatellite stable colorectal cancer.

Some 41 patients were evaluated in the study. The results demonstrated a 24% overall response rate with a 73% disease control rate.

Botensilimab was well tolerated, the company said.

Shares of the immuno-oncology company jumped 11% in Wednesday afternoon trading.

Price: 2.06, Change: +0.22, Percent Change: +11.68